U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H28O2
Molecular Weight 300.4359
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 4
Charge 0

SHOW SMILES / InChI
Structure of TRETINOIN

SMILES

C/C(=C(/[H])\C(\[H])=C(/[H])\C(=C(/[H])\C(=O)O)\C)/C(/[H])=C(\[H])/C1=C(C)CCCC1(C)C

InChI

InChIKey=SHGAZHPCJJPHSC-YCNIQYBTSA-N
InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+

HIDE SMILES / InChI
All-trans retinoic acid (ATRA) also known as tretinoin is an active metabolite of vitamin A that has been demonstrated to inhibit the growth of cancer cells, some types of epithelial cells, and vascular smooth muscles. It is medication used for the treatment of acne. Tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated. Tretinoin is for the induction of remission only. For acne it is applied to the skin as a cream or ointment. For leukemia it is taken by mouth for up to three months. The exact mechanism of action of tretinoin in APL and acne treatment is unknown, but is known, that tretinoin activates three members of the retinoid acid (RAR) nuclear receptors (RARα, RARβ, and RARγ) which act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation. It has not been established whether the clinical effects of tretinoin are mediated through activation of retinoic acid receptors, other mechanisms, or both.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RETIN-A

Approved Use

RETIN-A is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.

Launch Date

5.6764801E10
Palliative
TRETINOIN

Approved Use

retinoin Capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated. Tretinoin is for the induction of remission only. The optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for APL after completion of induction therapy with tretinoin.

Launch Date

1.18247037E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
314 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4055 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
24 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Disc. AE: Cheilitis, Skin xerosis...
AEs leading to
discontinuation/dose reduction:
Cheilitis
Skin xerosis
Desquamation
Headache
Skin xerosis
Sources: Page: p.348
1000 mg single, oral
Overdose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources: Page: p.74
unhealthy, 31
n = 1
Health Status: unhealthy
Condition: AIDS
Age Group: 31
Sex: M
Population Size: 1
Sources: Page: p.74
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea
Sources: Page: p.74
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
DLT: Hypercalcemia, Skin toxicity...
Dose limiting toxicities:
Hypercalcemia (grade 4, 22.2%)
Skin toxicity (grade 3, 33.3%)
Anemia (grade 3, 11.1%)
Thrombocytopenia (grade 3, 11.1%)
Emesis (grade 3, 11.1%)
Hypercalcemia (grade 3, 11.1%)
Sources: Page: p.897
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
DLT: Hypercalcemia, Skin toxicity...
Dose limiting toxicities:
Hypercalcemia (grade 4, 4.3%)
Skin toxicity (grade 3, 17.4%)
Emesis (grade 3, 4.3%)
AST/ALT ratio abnormal (grade 3, 4.3%)
Sources: Page: p.897
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.34
unhealthy, 4
n = 16
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 16
Sources: Page: p.34
1 mg/kg 2 times / day multiple, oral
Recommended
Dose: 1 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acne
Sources: Page: p.1
Disc. AE: Fetal damage...
AEs leading to
discontinuation/dose reduction:
Fetal damage (grade 4)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Cheilitis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Desquamation Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Headache Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Skin xerosis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Skin xerosis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Diarrhea Disc. AE
1000 mg single, oral
Overdose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources: Page: p.74
unhealthy, 31
n = 1
Health Status: unhealthy
Condition: AIDS
Age Group: 31
Sex: M
Population Size: 1
Sources: Page: p.74
Anemia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Emesis grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Hypercalcemia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Thrombocytopenia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Skin toxicity grade 3, 33.3%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Hypercalcemia grade 4, 22.2%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Skin toxicity grade 3, 17.4%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
AST/ALT ratio abnormal grade 3, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
Emesis grade 3, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
Hypercalcemia grade 4, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
Fetal damage grade 4
Disc. AE
1 mg/kg 2 times / day multiple, oral
Recommended
Dose: 1 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acne
Sources: Page: p.1
Overview

Overview

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
minor
minor
minor
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
[Tissue factor expression during all-trans retinoic acid or arsenic trioxide treatment in acute promyelocytic leukemia].
1998 Sep
All-trans retinoic acid-induced vasculitis and hemonecrosis of the ileum in a patient with acute promyelocytic leukemia.
1999 Apr
All-trans retinoic acid-induced multiple mononeuropathies.
1999 Apr
Upregulation of CHOP-10 (gadd153) expression in the mouse blastocyst as a response to stress.
1999 Dec
[An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
1999 Feb
Coronaric thrombotic events in acute promyelocytic leukemia during all-trans retinoic acid treatment: a role for adhesion molecules overexpression?
1999 Feb
Regulation of IL-5 and IL-5 receptor expression in the bone marrow of allergic asthmatics.
1999 Feb-Apr
Pseudotumour cerebri in acute promyelocytic leukemia: improvement despite continued ATRA therapy.
1999 Jul
Identification of heparin-binding EGF-like growth factor as a target in intercellular regulation of epidermal basal cell growth by suprabasal retinoic acid receptors.
1999 Mar 15
TCDD suppression of tissue transglutaminase stimulation by retinoids in malignant human keratinocytes.
2000 Aug
2,3,7,8-tetrachlorodibenzo-p-dioxin increases serum and kidney retinoic acid levels and kidney retinol esterification in the rat.
2000 Dec 1
Chelation of zinc amplifies induction of growth hormone mRNA levels in cultured rat pituitary tumor cells.
2000 Feb
All-trans-retinoic acid-induced myositis: a description of two patients.
2000 Feb
Therapeutic applications for ligands of retinoid receptors.
2000 Jan
The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution.
2000 Jan
Effects of retinoic acid on N-glycosylation and mRNA stability of the liver/bone/kidney alkaline phosphatase in neuronal cells.
2000 Jan
Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells.
2000 Jul
Regulation of retinoic acid signaling during lung morphogenesis.
2000 Jul
[Mechanism of tissue factor expression on NB4 cells down-regulated by all-trans retinoic acid and arsenic trioxide].
2000 May
Arsenic trioxide (As2O3) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells.
2000 May
Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients.
2000 Nov
Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.
2001 Apr
Regulation of aquaporin-4 expression in astrocytes.
2001 Apr 18
Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents.
2001 Aug 15
Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2.
2001 Dec 7
Inhibitors of arachidonic acid metabolism potentiate tumour necrosis factor-alpha-induced apoptosis in HL-60 cells.
2001 Jul 13
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.
2001 Jun
Characterization of a novel airway epithelial cell-specific short chain alcohol dehydrogenase/reductase gene whose expression is up-regulated by retinoids and is involved in the metabolism of retinol.
2001 Jun 29
1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects.
2001 May
Benign thymic hyperplasia after chemotherapy for acute myeloid leukemia.
2001 Oct
Retinoic acid prevents experimental Cushing syndrome.
2001 Oct
Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells.
2001 Oct
All-trans-retinoic acid increased the expression of integrin alpha5beta1 and induced "anoikis" in SMMC-7721 hepatocarcinoma cell.
2001 Sep
All-trans retinoic acid inhibits vascular smooth muscle cell proliferation targeting multiple genes for cyclins and cyclin-dependent kinases.
2001 Sep
Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator.
2002 Apr 1
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
2002 Aug 1
[Study of the effects of quercetin on PML gene and protein expression and localization in leukemia cells].
2002 Feb
Sequential induction of embryonic and adult forms of glutamic acid decarboxylase during in vitro-induced neurogenesis in cloned neuroectodermal cell-line, NE-7C2.
2002 Feb
Gene-specific TCDD suppression of RARalpha- and RXR-mediated induction of tissue transglutaminase.
2002 Jul
Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation, and transcriptional activity of retinoic acid receptor gamma 2.
2002 Jul 12
Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy.
2002 Jul-Aug
Excentric cleavage products of beta-carotene inhibit estrogen receptor positive and negative breast tumor cell growth in vitro and inhibit activator protein-1-mediated transcriptional activation.
2002 Jun
Analysis of cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid from patients with osteoarthritis and rheumatoid arthritis.
2002 Sep
All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia.
2003 Mar 1
Patents

Sample Use Guides

acute promyelocytic leukemia (APL): The recommended dose is 45 mg/m2/day administered as two evenly divided doses until complete remission is documented. Therapy should be discontinued 30 days after achievement of complete remission or after 90 days of treatment, whichever occurs first. acne vulgaris: RETIN-A Gel, Cream or Liquid should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Liquid: the liquid may be applied using a fingertip, gauze pad, or cotton swab. If gauze or cotton is employed, care should be taken not to oversaturate it, to the extent that the liquid would run into areas where treatment is not intended. Gel: Excessive application results in “pilling” of the gel, which minimizes the likelihood of over application by the patient.
Route of Administration: Other
Human bronchial SMCs were used and pretreated with or without tretinoin, also known as all-trans-retinoic acid (ATRA), (2 μM) for 20 min before the addition of PDGF (1 μg/ml), or ATRA alone. The neutral comet assay, which determines the incidence of double-stranded DNA breaks, was used to demonstrate that ATRA treatment induced apoptosis of bovine and human pulmonary artery SMC. In contrast, apoptotic cell death was not produced in response to ATRA in human bronchial airway SMC, as monitored by comet assay. Similarly, TUNEL assay and the measurement of mitochondrial membrane potential failed to demonstrate significant apoptosis by ATRA in airway SMCs. Positive controls, daunorubicin (DNR) and hydrogen peroxide, effectively elicited apoptosis in airway SMC. Because ATRA inhibited both morphologic and actin cytoskeletal changes induced by PDGF, it was characterized the effects of ATRA on PDGF-induced airway SMC migration using a modified Boyden chamber assay, which allows for determination of motility in random directions. PDGF caused a 4-fold increase in migration of airway SMCs after 24 h, and ATRA blocked these events. ATRA by itself had no effect. While the therapeutic level of ATRA in human plasma could reach 1–2 μM, the effects on airway SMC migration were observed with ATRA concentrations as low as 0.2 μM. DMSO, which is used as vehicle for ATRA and other retinoids, has no effect on PDGF-induced airway SMC migration. This does not appear to be due to the effects of ATRA on cell proliferation, as MTT assay showed that ATRA is not effective in inhibiting PDGF-induced cell proliferation; additionally, migration assay with 4 h of PDGF treatment also exhibits the ability of ATRA to inhibit migratory responses, as monitored using a modified Boyden chamber assay. Thus, although ATRA is ineffective in inhibiting proliferation and inducing apoptosis of airway SMCs, ATRA is an efficient inhibitor of airway SMC migration. Furthermore, using actinomycin D, a general inhibitor of gene transcription, showed that ATRA inhibition of SMC migration does not mediate gene transcriptional events.
Name Type Language
TRETINOIN
EP   HSDB   INN   JAN   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
TRETINOIN [ORANGE BOOK]
Common Name English
ORISTAR RNA
Brand Name English
TRETINOIN [JAN]
Common Name English
RETINOIC ACID [MI]
Common Name English
RETIN-A
Brand Name English
TRETINOIN COMPONENT OF VELTIN
Brand Name English
TRETINOIN COMPONENT OF SOLAGE
Common Name English
TRETINOIN [USP-RS]
Common Name English
TRI-LUMA COMPONENT TRETINOIN
Common Name English
SOLAGE COMPONENT TRETINOIN
Common Name English
VESANOID
Brand Name English
TRETINOIN [VANDF]
Common Name English
RETINOIC ACID
INCI   MI  
INCI  
Official Name English
RETIN A
Brand Name English
TRETINOIN [USAN]
Common Name English
TRETINOIN [MART.]
Common Name English
TRETINOIN [HSDB]
Common Name English
NSC-122758
Code English
TRETINOIN COMPONENT OF TRI-LUMA
Common Name English
TRETINOIN [USP]
Common Name English
KERLOCAL
Brand Name English
TRETINOIN [USP MONOGRAPH]
Common Name English
TRETINOIN [WHO-DD]
Common Name English
ZIANA COMPONENT TRETINOIN
Common Name English
TRETINOIN COMPONENT OF ZIANA
Common Name English
TRETINOIN [INN]
Common Name English
TRETINOIN [EP MONOGRAPH]
Common Name English
RENOVA
Brand Name English
ATRA
Common Name English
ALTRENO
Brand Name English
EUDYNA
Brand Name English
ABEREL
Brand Name English
ALL-TRANS-RETINOIC ACID
Common Name English
ALL-TRANS RETINOIC ACID
Common Name English
AVITA
Brand Name English
VELTIN COMPONENT TRETINOIN
Brand Name English
RETINOIC ACID [INCI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000007700
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NDF-RT N0000175607
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NCI_THESAURUS C68299
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-VATC QL01XX14
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
FDA ORPHAN DRUG 71692
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NCI_THESAURUS C804
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
FDA ORPHAN DRUG 5785
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
FDA ORPHAN DRUG 165802
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
LOINC 87673-0
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-VATC QD10AD51
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
FDA ORPHAN DRUG 50990
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-ATC D10AD51
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NDF-RT N0000007700
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NDF-RT N0000007700
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-ATC D10AD01
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-VATC QD10AD01
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
WHO-ATC L01XX14
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NDF-RT N0000007700
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
NDF-RT N0000007700
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
LIVERTOX 993
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL38
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
DRUG CENTRAL
2722
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
MERCK INDEX
M9558
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY Merck Index
INN
2875
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
PUBCHEM
444795
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
FDA UNII
5688UTC01R
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
RXCUI
221175
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
ALTERNATIVE
NCI_THESAURUS
C900
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
WIKIPEDIA
TRETINOIN
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
RXCUI
10753
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
DRUG BANK
DB00755
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
LACTMED
Tretinoin
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
CAS
302-79-4
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
IUPHAR
2644
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
HSDB
2169
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
EVMPD
SUB11246MIG
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
EPA CompTox
302-79-4
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
USP_CATALOG
1674004
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY USP-RS
ECHA (EC/EINECS)
206-129-0
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY
MESH
D014212
Created by admin on Fri Jun 25 20:57:59 UTC 2021 , Edited by admin on Fri Jun 25 20:57:59 UTC 2021
PRIMARY